Treatment of Ocular Inflammatory Disorders with Adalimumab: A Retrospective Case Series
To determine the efficacy and safety of adalimumab in the treatment of ocular inflammatory disorders the records of five patients with sight-threatening ocular inflammatory disorders resistant to other immunosuppressive agents treated with Adalimumab 20-40 mg every two weeks were analyzed. A total of 5 patients: two patients had Behcet's disease; 1 had juvenile idiopathic arthritis-associated uveitis, 1 had anterior uveitis secondary to ankylosing spondylitis, and 1 had Idiopathic nodular scleritis. Five patients were treated (eight eyes examined) with Adalimumab; 4 males and 1 female, ranging in ages 9 to 52 years (mean: 27-years-old). All patients except patient 4 and 5 showed marked improvement in signs of ocular inflammation within 4 weeks from onset of therapy. However, patientsâ€™ No. 4 and 5 showed complete improvement in signs of ocular inflammation within 6 and 12 weeks, respectively.
Copyright (c) 2008 Journal of King Abdulaziz University - Medical Sciences
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.